Samarium Therapy

Samarium Therapy is a radiopharmaceutical treatment modality that employs samarium-153 lexidronam, a beta-emitting radionuclide, to selectively target and ablate metastatic bone lesions for the palliation of cancer-induced skeletal pain.

27

Publications

1.2K

Citations

175

Authors

65

Institutions

Publications per year

2017–2026

0

Variants

Samarium-153 Lexidronam Therapy

Authors

175

  1. AG
    A. Guirguis

    NewYork–Presbyterian Brooklyn Methodist Hospital, United States

    2 publications · 76 citations

    2

    h-index

  2. HA
    Hani Ashamalla

    NewYork–Presbyterian Brooklyn Methodist Hospital, United States

    2 publications · 76 citations

    2

    h-index

  3. RD
    Ryan D. Stephenson

    Cornell University, United States

    2 publications · 126 citations

    2

    h-index

  4. SM
    Steven M. Larson

    Memorial Sloan Kettering Cancer Center, United States

    2 publications · 126 citations

    2

    h-index

  5. MJ
    Michael J. Morris

    Memorial Sloan Kettering Cancer Center, United States

    2 publications · 126 citations

    2

    h-index

1–5 of 175

Venues

  1. PubMed

    Repository · 3 publications · 67 citations

    3

    h-index

  2. Journal of Clinical Oncology

    2 publications · 273 citations

    2

    h-index

  3. Nuklearmedizin - NuclearMedicine

    2 publications · 84 citations

    2

    h-index

  4. Clinical Cancer Research

    2 publications · 126 citations

    2

    h-index

  5. 2

    h-index

1–5